Citation Impact
Citing Papers
Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
2011
Hallmarks of Cancer: The Next Generation
2011 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Long‐term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas
2005
The Medical Treatment of Cushing’s Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery
2008
Acromegaly
2006 Standout
Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease
2009
The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly
2005
Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study1
1998
Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy
1995
Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole?
2013
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
2006
Hyperprolactinaemia in 271 women: up to three decades of clinical follow‐up
2005
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
2019 Standout
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
2016 Standout
Dopamine Resistance of Prolactinomas
2003
Pharmacotherapy or Surgery as Primary Treatment for Acromegaly?
2000
Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients
2009
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
Cushing's syndrome
2015 Standout
Cabergoline monotherapy in the long-term treatment of Cushing's disease
2010
Molecular defects in the pathogenesis of pituitary tumours
2003
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Diagnosis and Treatment of Pituitary Tumors
1999
The biology and function of fibroblasts in cancer
2016 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Coordinated regulation of myeloid cells by tumours
2012 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid
2014 StandoutNature
The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males
2006
Prolactinomas and Pregnancy
2005
Management of Pituitary Tumours: Strategy for Investigation and Follow-Up
2000
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Paracrine Interactions within the Pituitary Gland
1998
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Prolactinomas
2010
Cabergoline and the risk of valvular lesions in endocrine disease.
2008
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders
2000
Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?
1998
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
MEDICAL TREATMENT OF PROLACTINOMAS
1999
Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease
2008
Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor Shrinkage
2006
Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone
2003
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
1997
Acromegaly
1994
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
2011 Standout
Leukocytes in Mammary Development and Cancer
2010
Nelson’s Syndrome: Complete Remission with Cabergoline but Not with Bromocriptine or Cyproheptadine Treatment
2004
CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+T cells
2013
Prolactinoma
2003
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families
1998 StandoutNobel
Pregnancy outcomes following cabergoline treatment: extended results from a 12‐year observational study
2007
Pituitary Disorders During Pregnancy
2006
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
2013 Standout
Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors
2004
Bioactive peptides in anterior pituitary cells
1994
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
2013 StandoutNobel
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Growth-hormone and prolactin excess
1998
Hyperprolactinemia and Prolactinomas
2008
Origin and physiological roles of inflammation
2008 StandoutNature
Prognostic relevance of cancer-associated fibroblasts in human cancer
2014
Macrophage plasticity and polarization: in vivo veritas
2012 Standout
Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.
1997
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Toll-like receptors: critical proteins linking innate and acquired immunity
2001 Standout
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms
2013 Standout
Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
2010
Retinoic Acid as a Novel Medical Therapy for Cushing’s Disease in Dogs
2006
Cushing's syndrome
2006 Standout
Medical therapy for clinically non-functioning pituitary adenomas
2008
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
2002 Standout
Extracellular small heat shock proteins: exosomal biogenesis and function
2017
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Diagnosis and management of hyperprolactinemia: Results of a Brazilian multicenter study with 1234 patients
2008
Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression
2014
Effect of Different Dopaminergic Agents in the Treatment of Acromegaly
1997
Bispecific antibodies: a mechanistic review of the pipeline
2019
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
1997
Pathogen Recognition and Innate Immunity
2006 Standout
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
2011 StandoutNature
Do the limits of serum prolactin in disconnection hyperprolactinaemia need re‐definition? A study of 226 patients with histologically verified non‐functioning pituitary macroadenoma
2006
Pituitary Tumor Registry: A Novel Clinical Resource1
2000
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
2003
Pregnancy outcome after treatment with the ergot derivative, cabergoline
1996
Toll-like receptors and innate immunity
2001 Standout
Pathophysiology of Human Visceral Obesity: An Update
2013 Standout
Toll-Like Receptors
2003 Standout
Individualized High-Dose Cabergoline Therapy for Hyperprolactinemic Infertility in Women with Micro- and Macroprolactinomas
2010
Exosomes
2019 Standout
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly
2002
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
Six Months of Treatment with Cabergoline Restores Sexual Potency in Hyperprolactinemic Males: An Open Longitudinal Study Monitoring Nocturnal Penile Tumescence
2004
Leukocyte composition of human breast cancer
2011
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
2004 Standout
Suppression of Rat and Human Growth Hormone and Prolactin Secretion by a Novel Somatostatin/Dopaminergic Chimeric Ligand
2003
Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients
1998
Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients
2008
Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients
1999
Advances in the Treatment of Prolactinomas
2006
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
1997
Long-Term Treatment of Prolactin-Secreting Macroadenomas with Pergolide
2000
A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling
2000
Modular repeat protein sculpting using rigid helical junctions
2020 StandoutNobel
Interleukin-10 and the Interleukin-10 Receptor
2001 Standout
Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study
2013 Standout
Prolactin: Structure, Function, and Regulation of Secretion
2000 Standout
The Molecular Pathogenesis of Corticotroph Tumors
1999
Primary Medical Therapy for Acromegaly: An Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-Like Growth Factor-I, and Tumor Size
2002
Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2
2003
Resistance to Cabergoline as Compared with Bromocriptine in Hyperprolactinemia: Prevalence, Clinical Definition, and Therapeutic Strategy
2001
Pluripotency and nuclear reprogramming
2008 StandoutNobel
Diverse Functions of Macrophages in Different Tumor Microenvironments
2018
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists: A Prospective Study in 110 Patients1
2000
Dopamine Receptor Expression and Function in Corticotroph Ectopic Tumors
2006
Primary Medical Therapy of Micro- and Macroprolactinomas in Men*
2000
Long-Term Treatment of Prolactin-Secreting Macroadenomas with Pergolide
2000
Distribution and Abundance of Messenger Ribonucleic Acid for Growth Hormone Receptor Isoforms in Human Tissues1
2000
Innate Immune Recognition
2002 Standout
Leukemia-Inhibitory Factor—Neuroimmune Modulator of Endocrine Function*
2000
Angiogenesis in Endocrine Tumors
2003
The Cytogenesis and Pathogenesis of Pituitary Adenomas*
1998
Plant and Animal Sensors of Conserved Microbial Signatures
2010 StandoutScienceNobel
Role of Extracellular Matrix in Adaptation of Tendon and Skeletal Muscle to Mechanical Loading
2004 Standout
Regulation of the Hypothalamic-Pituitary-Adrenal Axis by Cytokines: Actions and Mechanisms of Action
1999
Pituitary Corticotroph SOCS-3: Novel Intracellular Regulation of Leukemia-Inhibitory Factor-Mediated Proopiomelanocortin Gene Expression and Adrenocorticotropin Secretion
1998
Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter
1999
Systematic methodological review: developing a framework for a qualitative semi‐structured interview guide
2016 Standout
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Works of Jonathan Webster being referenced
Dose‐dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study
1992
Variations in stromal signatures in breast and colorectal cancer metastases
2010
Clinical management of prolactinomas
1999
Chaperone Activity of Small Heat Shock Proteins Underlies Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis
2012
Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion.
1995
A Comparative Review of the Tolerability Profiles of Dopamine Agonists in the Treatment of Hyperprolactinaemia and Inhibition of Lactation
1996
Dopamine Agonists and Pituitary Tumor Shrinkage
1992
AMP is a component of the low molecular weight mitogenic activity present in human pituitary tumours.
1996
Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ
2009
Studies with a Growth Hormone Antagonist and Dual-fluorescent Confocal Microscopy Demonstrate that the Full-length Human Growth Hormone Receptor, but Not the Truncated Isoform, Is Very Rapidly Internalized Independent of Jak2-Stat5 Signaling
1999
Preliminary Characterization of Growth Factors Secreted by Human Pituitary Tumors
1991
The efficacy and tolerability of long‐term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study
1993
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
1994
Hyperprolactinemia: Etiology, Diagnosis, and Management
2002
Growth factors and pituitary tumors
1989
Qualitative Research in Health Care
2005
Guidelines for the diagnosis and treatment of hyperprolactinemia.
1999
Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study
2018
Growth factors and the anterior pituitary
1991